Zuranolone Mechanism of Action: GABA Receptor Modulation

Zuranolone works by boosting the activity of GABA-A receptors throughout the brain, the main receptors responsible for calming neural activity. Unlike traditional antidepressants that target serotonin or norepinephrine and take weeks to show results, zuranolone is a synthetic neuroactive steroid designed to restore inhibitory signaling rapidly, with measurable symptom improvement appearing within days. The drug’s mechanism touches on a fundamentally different model of how depression develops and how it can be reversed, one rooted not in monoamine neurotransmitter levels but in the brain’s excitation-inhibition balance.

A Positive Allosteric Modulator, Not a Direct Activator

Zuranolone belongs to a class called positive allosteric modulators (PAMs) of GABA-A receptors. That means it does not switch on these receptors by itself. Instead, it latches onto a site on the receptor that is separate from where GABA, the brain’s primary inhibitory neurotransmitter, normally binds. When GABA arrives and opens the receptor’s chloride channel, zuranolone amplifies the effect, making the channel stay open longer or open more fully. The result is stronger inhibitory signaling without the drug acting as an on-off switch.

This distinction matters because it preserves the brain’s own signaling rhythm. GABA-A receptors only get amplified when GABA is already being released at that synapse or that extrasynaptic site. In preclinical testing, zuranolone acted as a PAM at all nine receptor subunit combinations tested, confirming broad activity across the various forms these receptors take in different brain regions.¹

Synaptic and Extrasynaptic Receptors

GABA-A receptors come in two broad functional categories based on where they sit on neurons. Synaptic receptors cluster at the junctions between neurons and handle fast, brief bursts of inhibition each time a neighboring neuron fires. Extrasynaptic receptors sit outside those junctions and respond to low, ambient levels of GABA that float through the surrounding fluid, providing a slower, sustained background of inhibitory tone. This tonic inhibition is thought to set the overall excitability level of neural circuits.

Zuranolone acts on both types. At the most common synaptic receptor configuration (containing the α1, β2, and γ2 subunits), it enhanced GABA currents with an EC50 of 430 nM. At the most common extrasynaptic configuration (containing α4, β3, and δ subunits), it was even more potent, with an EC50 of 118 nM.² That dual action is central to the drug’s antidepressant rationale. The hypothesis is that depression involves a breakdown in the balance between excitatory and inhibitory neural circuits, and restoring inhibitory tone at both the fast (synaptic) and slow (extrasynaptic) level helps reset that balance. This is what researchers mean when they describe zuranolone as working to “restore network balance in brain areas dysregulated in depression.”³

How Zuranolone Differs from Benzodiazepines

Benzodiazepines like diazepam and alprazolam also enhance GABA-A receptor activity, so a natural question is why zuranolone would work as an antidepressant when benzodiazepines do not. The answer comes down to which receptors each drug class can reach. Benzodiazepines only work at synaptic GABA-A receptors, specifically those containing a γ subunit. They have no meaningful effect on the extrasynaptic, δ-subunit-containing receptors that provide tonic inhibition.

Research in animal models of social defeat stress found that neuroactive steroids like zuranolone increased theta oscillations in the basolateral amygdala and medial prefrontal cortex through activation of those δ-subunit-containing receptors, and this change was tied to antidepressant-like behavior. Benzodiazepines did not produce this effect.⁴ Theta oscillations in these regions are linked to emotional regulation and mood, so the capacity to modulate them through extrasynaptic receptors appears to be a key piece of why neuroactive steroids have antidepressant properties that benzodiazepines lack.

Zuranolone also binds at a different physical site on the receptor than benzodiazepines do. In lab experiments, zuranolone and diazepam potentiated GABA currents together in an additive fashion at synaptic receptors, confirming their binding sites are distinct and non-competitive.⁵ This is consistent with the known pharmacology of neurosteroids, which interact with a transmembrane binding pocket on GABA-A receptors that is entirely separate from the benzodiazepine site.

The Connection to Natural Neurosteroids

Zuranolone is a synthetic analog of allopregnanolone, a neurosteroid the body produces naturally from progesterone. Allopregnanolone is one of the brain’s own GABA-A receptor modulators and has anxiolytic, sedative, and anticonvulsant properties.⁶ During pregnancy, allopregnanolone levels rise dramatically, and the brain adapts by changing the composition of its GABA-A receptors. Both the γ2 subunit (synaptic) and the δ subunit (extrasynaptic) decrease in expression during prolonged high-steroid exposure.⁷

After delivery, allopregnanolone levels plummet as progesterone drops. The brain, having downregulated its GABA-A receptor subunits during pregnancy, is now left in a state of reduced inhibitory capacity with the natural modulator suddenly gone. This mismatch between receptor availability and neurosteroid levels is one of the leading hypotheses for why some people develop postpartum depression. Zuranolone, by acting as a potent replacement at exactly these receptor types, may bridge the gap while the brain’s receptor population readjusts.

This hormonal context also helps explain why zuranolone and its predecessor brexanolone (an intravenous formulation of allopregnanolone itself) have shown particular effectiveness in postpartum depression. A meta-analysis found that zuranolone showed somewhat greater efficacy in postpartum-onset depression than in general major depressive disorder, though the difference did not reach statistical significance.⁸

Why It Works Faster Than Traditional Antidepressants

Standard antidepressants like SSRIs and SNRIs alter serotonin or norepinephrine signaling and then rely on slow downstream adaptations, including receptor density changes and gene expression shifts, that take weeks to produce meaningful mood improvement. Zuranolone’s mechanism is more direct: it amplifies inhibitory signaling through existing GABA-A receptors without waiting for the brain to remodel itself.

Clinical trials have consistently shown symptom improvement within the first few days of treatment. In a phase 3 trial in adults with major depressive disorder, patients on zuranolone showed greater improvement in depression scores compared with placebo by day 3, a difference that persisted through the end of the two-week treatment course and was sustained at follow-up through day 42.⁹ A pharmacokinetic modeling study estimated that zuranolone’s onset rate constant was roughly ten times faster than amitriptyline’s and nearly 28 times faster than escitalopram’s.¹⁰

In brain slice experiments, zuranolone also produced a sustained increase in GABA currents that appeared to involve trafficking of additional GABA-A receptors to the cell surface, a process known as metabotropic receptor trafficking.¹¹ This means zuranolone may not only amplify the receptors already in place but also promote the insertion of more receptors into the neuron’s membrane, potentially explaining why its effects appear to outlast its presence in the bloodstream.

The 14-Day Treatment Course

One of the most unusual features of zuranolone is that it is prescribed as a 14-day once-daily course rather than as a continuous daily medication. Most antidepressants are taken indefinitely or for many months. The short-course design reflects the idea that zuranolone is resetting a neural circuit imbalance rather than indefinitely supplementing a neurotransmitter.

Clinical data supports this approach. In the phase 3 MDD trial, the improvement seen by the end of the 14-day dosing period persisted through day 42, a full four weeks after the last dose.¹² A Japanese phase 3 trial similarly found significant improvement from baseline on the primary depression measure by day 3, day 8, and day 15.¹³ This durability beyond the dosing window is consistent with the receptor-trafficking hypothesis: if zuranolone promotes the insertion of additional GABA-A receptors into the membrane, those receptors could continue functioning after the drug itself is cleared.

The meta-analysis across zuranolone trials found that the drug roughly doubled the odds of both response and remission compared with placebo, with the optimal dose appearing to be 30 mg daily. Above that dose, side effects increased without a proportional gain in efficacy.¹⁴

Side Effects Tied to the Mechanism

Because zuranolone enhances inhibitory GABA signaling broadly, its most common side effects are sedation-related. In clinical trials, the adverse events that occurred more frequently with zuranolone than with placebo at rates above 5% included somnolence, dizziness, sedation, and fatigue.¹⁵ These make intuitive sense: GABA is the brain’s brake pedal, and pressing it harder produces drowsiness as a predictable byproduct.

These side effects are most pronounced shortly after dosing, which is why zuranolone is taken in the evening with a fatty meal (fat improves absorption). The meta-analysis noted that although side effects were more common overall with zuranolone than placebo, dropout rates were not significantly different between groups, suggesting the side effects were tolerable enough that most patients completed the 14-day course.¹⁶

One concern with any GABAergic drug is whether it impairs thinking. In a phase 1 study of healthy adults, researchers examined zuranolone’s pharmacokinetic interactions with alprazolam and ethanol. They found that zuranolone’s blood levels remained relatively unchanged when given alongside either substance, and zuranolone did not meaningfully alter alprazolam or ethanol levels either. Both zuranolone and alprazolam are processed by the same liver enzyme (CYP3A4), but neither drug inhibits or induces that enzyme, so no pharmacokinetic interaction occurred.¹⁷ That said, combining any two drugs that both dampen brain activity can increase sedation and impairment even without a pharmacokinetic interaction, so the absence of a drug-level change does not mean mixing them is without risk.

Breast Milk Transfer and Postpartum Use

Given that zuranolone’s FDA approval is specifically for postpartum depression, the question of breast milk transfer is clinically important. A phase 1 study in healthy lactating women found that zuranolone transfer into breast milk was low. At the 30 mg dose, the mean relative infant dose (the percentage of the mother’s weight-adjusted dose that the infant would receive through milk) was about 0.36%. Even with simulations of the higher 50 mg dose taken daily for 14 days, the estimated relative infant dose stayed below 1%, well under the 10% threshold that pharmacologists generally consider compatible with breastfeeding.¹⁸ The transfer was comparable to or lower than levels reported for common antidepressants like sertraline or paroxetine.

This matters because one of the barriers to treating postpartum depression is the concern that medication will reach the nursing infant. If the drug that works fastest for postpartum depression also passes into breast milk at very low levels, it removes a significant practical obstacle for new parents weighing treatment options.

Potential Applications Beyond Depression

The rapid-onset nature of zuranolone’s mechanism has drawn interest for situations where waiting weeks for an antidepressant to work is especially problematic. One commentary highlighted palliative care as a setting where patients with limited life expectancy may develop depression but do not have weeks to wait for a standard antidepressant to take effect.¹⁹

Early-stage research is also exploring zuranolone’s effects on neuroinflammation. In mouse models of postoperative delirium and systemic inflammation, zuranolone reduced microglial density and activation markers in the brain, with particularly strong effects in inflammation-driven and age-related contexts.²⁰ Microglia are the brain’s resident immune cells, and their overactivation has been implicated in both delirium and depression. This is still preclinical work, but it suggests that zuranolone’s effects may extend beyond receptor-level signaling changes to include dampening of neuroinflammatory processes. Whether this is a direct effect of GABA-A modulation on immune cell activity or an indirect consequence of restored neural circuit function is not yet clear.

How the GABA Model Challenges the Serotonin Story

For decades, the dominant explanation for depression centered on monoamine neurotransmitters, particularly serotonin. Most widely prescribed antidepressants work by increasing serotonin availability. Zuranolone’s success represents a meaningful challenge to that framework, or at least a broadening of it. Its mechanism does not involve serotonin, norepinephrine, or dopamine at all. Instead, it targets the brain’s inhibitory system directly.

The evidence that zuranolone works is now fairly solid across multiple trials. The meta-analysis of trials found a moderate overall reduction in depressive symptoms, with an effect size of about −0.37, and the drug also reduced anxiety symptoms.²¹ That effect size is modest by some standards, but the speed of onset and the short duration of treatment represent something genuinely new. Traditional antidepressants generally take four to six weeks to show their full effect, and treatment often extends for months or years. A two-week course that produces measurable improvement within three days is a different kind of intervention entirely.

Whether zuranolone’s mechanism will eventually be understood as correcting the “real” cause of certain depressions, or whether it is a useful shortcut that bypasses the root problem, remains an open question. The hormonal link in postpartum depression gives the clearest mechanistic story: neurosteroid levels crash, GABA-A receptor composition has shifted, and a synthetic neurosteroid fills the gap. In non-postpartum major depression, the rationale is less tidy, but the clinical data suggests the excitation-inhibition imbalance framework captures something real about at least a subset of depressive episodes.

Co-Initiation with Standard Antidepressants

Zuranolone is also being studied as a bridge therapy, started at the same time as a traditional antidepressant to cover the lag period before that antidepressant kicks in. The CORAL trial tested zuranolone given alongside a newly started standard antidepressant in adults with major depressive disorder.²² The logic is straightforward: zuranolone provides rapid relief through GABA modulation during the first two weeks while the SSRI or SNRI builds up its slower-acting serotonergic effects. Once the zuranolone course is done, the conventional antidepressant has had time to reach therapeutic levels and can maintain improvement on its own.

This approach is particularly interesting because it treats zuranolone’s rapid but potentially time-limited mechanism as complementary to, rather than a replacement for, conventional therapy. If the two-week zuranolone course resets inhibitory tone and the standard antidepressant maintains mood through a separate mechanism, the combination could solve both the speed problem and the durability problem in a single treatment plan. Whether this combination strategy proves more effective than either drug alone, and whether the benefits justify the added cost and side-effect exposure, are questions the ongoing LANDSCAPE trial program is designed to answer.